

On page 66, line 28, kindly insert -- SEQ ID NO 1 -- after
"....LLK".

On page 67, line 24, kindly insert -- SEQ ID NO 1 -- after
"....LLK".

On page 67, line 27, kindly insert -- SEQ ID NO 1 -- after
"....LLK".

IN THE CLAIMS:

1. (Amended) A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a linear polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula $(Z_aU_b)_cZ_d$, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of V, I, L, C, Y and F;

a has an average value of about 1 to about 5;

b has an average value of about 3 to about 20;

c is 1 to 10; and

d is 1 to 3;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

Kindly add new claims 6, 7, and 8, as follows:

6. A synthetic pulmonary surfactant comprising two pharmaceutically acceptable phospholipids admixed with a fatty acid and a polypeptide having an amino acid residue sequence represented by the formula:

KLLLLKLLLLKLLLLKLLLLK.

A 4
cont'd.

Serial No.: 07/715,397

7. A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a linear polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula $(Z_aU_b)_cZ_d$, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;

a is 1 or 2;

b has an average value of about 3 to about 8;

c is 1 to 10; and

d is 0 to 2;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

A copied

8. The synthetic pulmonary surfactant of claim 7, said polypeptide having an amino acid residue sequence selected from the group consisting of:

RLLLLRLLLLRLLLLRLLLLR,
RLLLLLRLRLRLRLRLRLRL,
RRLLLLLRLRLRLRLRLRLRL,
RLLLLCLLLRLLLLCLLLR,
RLLLLCLLLRLLLLCLLLRLL,
RLLLLCLLLRLLLLCLLLRLLR,
KLLLLKLLLLKLLLLKLLLLK,
KLLLLLKLKLKLKLKLKL, and
KKLLLLLKLKLKLKLKLKL.